Drug updated on 10/30/2024
| Dosage Form | granules (oral; 2 g/packet) |
| Drug Class | Nitroimidazole antimicrobials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older
- Indicated for the treatment of trichomoniasis in patients 12 years of age and older.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Secnidazole (2 g) significantly reduced the risk of bacterial vaginosis (BV) in patients with three or fewer episodes in the last year (OR (odds ratio): 7.54, 95% CI (confidence interval): 3.89-14.60, p < 0.00001) and in those with four or more episodes (OR: 4.74, 95% CI: 1.51-14.84, p = 0.008).
- Secnidazole (2 g) also increased the microbiologic cure rate in women with three or fewer episodes of BV (OR: 7.63, 95% CI: 2.30-25.33, p = 0.0009) and those with four or more episodes (OR: 20.17, 95% CI: 1.06-382.45, p = 0.05).
- The clinical cure rate of secnidazole (2 g) was comparable to other treatments, including metronidazole (500 mg bid for 5 days), single-dose oral metronidazole, and combination therapies.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Solosec (secnidazole) Prescribing Information. | 2022 | Lupin Pharmaceuticals Inc., Baltimore, MD |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Secnidazole for treatment of bacterial vaginosis: a systematic review | 2019 | BMC Womens Health |